Archives
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
- 2021-12
- 2021-11
- 2021-10
- 2021-09
- 2021-08
- 2021-07
- 2021-06
- 2021-05
- 2021-04
- 2021-03
- 2021-02
- 2021-01
- 2020-12
- 2020-11
- 2020-10
- 2020-09
- 2020-08
- 2020-07
- 2020-06
- 2020-05
- 2020-04
- 2020-03
- 2020-02
- 2020-01
- 2019-12
- 2019-11
- 2019-10
- 2019-09
- 2019-08
- 2019-07
- 2019-06
- 2019-05
- 2019-04
- 2018-07
-
The putative residue apelin proprotein proapelin
2022-11-09

The putative 55-residue apelin proprotein (proapelin or apelin-55) is processed from a 77-residue preproprotein through removal of a 22-residue signal peptide (Table 1). Apelin-55 is further processed into bioactive isoforms of 36, 17, or 13 residues, likely through protease-mediated mechanisms. To
-
br HIF Blockade in AA Therapy In lieu of
2022-11-09

HIF-α Blockade in AA Therapy In lieu of the evidence supporting a central role for HIF-α signaling in tumor angiogenesis and CC pathobiology, significant efforts have focused on the discovery of small-molecule HIF-α inhibitors (for exhaustive compendia, see [28,44,45]). In brief, inhibitors vary
-
Breast Cancer Although androgens have been
2022-11-09

Breast Cancer: Although androgens have been considered to be a risk factor in prostate cancer they have been recommended to treat breast cancers. Even before the discovery of SERMs and aromatase inhibitors, steroidal androgens such as medroxyprogesterone and fluoxymesterone were used to treat breast
-
The major phase trial NCT enrolled participants
2022-11-09

The major phase 2 trial (NCT01343966) enrolled 431 participants with mild to moderate AD who received either low-dose SC crenezumab 300 mg or placebo biweekly (n = 184) or high-dose intravenous crenezumab 15 mg/kg or placebo every 4 weeks (n = 247) for 68 weeks 38, 40. No significant treatment benef
-
The glutamate receptors are important to the
2022-11-09

The glutamate receptors are important to the glioma Nimodipine from escaping the excitotoxicity under physiological conditions. There are three subtypes of ionotropic glutamate receptors, including NMDA, kainate, and AMPA receptors, which are relating to diverse Ca2+ permeability. Glioma cells also
-
br Depletion of serum amino acids Currently
2022-11-09

Depletion of serum amino acids Currently, the only anticancer agents that directly target amino 4SC-202 metabolism are bacterial l-asparaginases (from Escherichia coli and Erwinia chrysanthemi), which are FDA-approved for treatment of pediatric and adult ALL. A potential complication of using ba
-
br Discussion The clinical course of our
2022-11-08

Discussion The clinical course of our patient until May 2012 was rather typical of early onset AChR-MG. Later on, the pattern of the disease was more typical of MuSK-MG, as evidenced by the distribution of myasthenic weakness and the unprovoked exacerbations. The EHop-016 of MuSK-MG appears to b
-
Eicosanoids are locally acting signaling
2022-11-08

Eicosanoids are locally acting signaling lipids that are produced from C20 polyunsaturated fatty acids (PUFAs), including arachidonic Rufinamide (AA, C20:4), eicosapentaenoic acid (C20:5) and eicosatrienoic acid (C20:3) (Dennis and Norris, 2015; Funk, 2001; Stables and Gilroy, 2011). According to t
-
The presence of different LO splice variants was
2022-11-08

The presence of different 5-LO splice variants was first demonstrated in human Caspase-3, human recombinant proteinase synthesis tumour cells and in dimethyl sulfoxide-differentiated HL-60 cells [40] and a correlation between the 5-LO splicing pattern and the malignancy of the brain tumours was fou
-
At present drugs that specifically inhibit
2022-11-08

At present, drugs that specifically inhibit YAP activity are not available. In fact, verteporfin, which was originally described as a specific inhibitor of YAP-TEAD interaction, has been recently shown to exert its activity through selective induction of proteotoxicity rather than through YAP inhibi
-
br The future of cancer therapeutics with Aurora
2022-11-08

The future of cancer therapeutics with Aurora kinase inhibitors Involvement of Aurora kinases in deregulating multiple tumor suppressor and oncogenic pathways together with the preclinical findings on the efficacy of Aurora kinase inhibitors in attenuating growth of tumor Fructose Colorimetric/Fl
-
From a clinical utility standpoint this study showed that AR
2022-11-07

From a clinical utility standpoint, this study showed that AR can be useful in the GATA3-positive tumor of unknown origin setting. Epidemiologically, in this setting, the top 2 diagnoses in the differential diagnosis are metastatic carcinoma of breast origin or urothelial origin [18]. Seven out of 1
-
Detailed analysis of the dose dependence of A effects reveal
2022-11-07

Detailed analysis of the dose dependence of Aβ effects revealed that at low amounts, Aβ can also act as a positive regulator of presynaptic activity, enhancing the neurotransmitter release probability and increasing the neuronal excitability [2]. The facilitator effects of low Aβ dose on excitatory
-
br Concluding Remarks and Future Perspectives
2022-11-07

Concluding Remarks and Future Perspectives Herein, we have highlighted our current understanding of the role of the LKB1-AMPK pathway and its related kinases in β cell biology. β cell-specific genetic models have been particularly useful in delineating precise roles for individual family members
-
Based on their different sources the APN inhibitors APNIs
2022-11-07

Based on their different sources, the APN inhibitors (APNIs) can be divided into the natural products and synthetic compounds. Bestatin (1, Fig. 1), isolated from the Streptomyces oliuoreticuli by Umezawa et al., is the first reported and only marketed natural dipeptidomimetic inhibitor of APN. Afte
15575 records 352/1039 page Previous Next First page 上5页 351352353354355 下5页 Last page